In a last step, we aimed to identify THOP1 as biomarker of sensitivity to the prodrugs by correlating tumor growth delay compared to control with the THOP1 expression level of each xenograft as determined by ELISA and IHC. The gene discussed is THOP1; the disease is neoplasm.